SIGY Archives - Page 2 of 3

Developments

Sigyn Therapeutics to begin trading on OTCQB today

Shares of Sigyn Therapeutics (OTCQB:SIGY) will begin trading on the OTCQB Venture Exchange at the market open today. The company’s securities, which previously traded on the OTC Pink Market, will continue to trade...

August 3, 2022

Executive Moves

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...

April 26, 2022

Executive Moves

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Ajay Verma Sigyn Therapeutics (OTC:SIGY) appointed Ajay Verma, M.D., Ph.D., a recognized thought leader in the field of neurology, to its scientific advisory board. Dr. Verma’s extensive clinical experience and insights...

March 31, 2022

Executive Moves

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Sigyn Therapeutics (OTC:SIGY) appointed internationally recognized nephrologist, H. David Humes, M.D., to its scientific advisory board. Dr. Humes recently played an instrumental role in the oversight of preclinical...

March 15, 2022

Executive Moves

Sigyn appoints internationally recognized nephrologist Dr. Alexander Yevzlin to SAB

Sigyn Therapeutics (OTC:SIGY) appointed Alexander Yevzlin, M.D., currently prof. of medicine and director of interventional nephrology at the University of Michigan, to its scientific advisory board. Dr...

March 9, 2022

Executive Moves

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics (OTC:SIGY) appointed Jeremy Ferrell as CFO, effective March 9, 2022, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping manage Sigyn’s...

March 2, 2022

Developments

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics (OTC:SIGY) reported successful completion of an in vivo study that demonstrated Sigyn Therapy, its novel blood purification technology, to be safe and well tolerated. Data resulting from...

February 23, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Developments

Sigyn Therapeutics featured in BioSpace, twice

BioSpace, a leading life sciences publication, featured Sigyn Therapeutics (OTC:SIGY) and its novel extracorporeal blood purification technology twice in January. One article profiled the company and its Sigyn...

January 19, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Tag - SIGY

Sigyn Therapeutics to begin trading on OTCQB today

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Sigyn appoints internationally recognized nephrologist Dr. Alexander Yevzlin to SAB

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics featured in BioSpace, twice

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

General

More